Buchholz, Angela
Berner, Michael
Dams, Judith
Rosahl, Anke
Hempleman, Jochen
König, Hans-Helmut
Konnopka, Alexander
Kriston, Levente
Piontek, Daniela
Reimer, Jens
Röhrig, Jeanette
Scherbaum, Norbert
Silkens, Anna
Kraus, Ludwig
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 31 May 2021
Accepted: 13 January 2022
First Online: 27 January 2022
Declarations
:
: Ethical approval was granted in accordance with the principles of the Declaration of Helsinki. The study including an elaborated study protocol (experimental protocol) describing all study procedures, assessment instruments, as well as ethical and data protection measures, was approved by the ethics committee of the local medical association in Hamburg (“Ärztekammer Hamburg”; reference number PV4325) and the ethics committee at each of the participating sites. Informed consent was obtained from all patients.
: Not applicable.
: The authors do not have any connection with the tobacco, alcohol, pharmaceutical or gaming industry that are related to the current research, research contracts, consultancy, employment or financial interests. There are no existing contractual constraints on publishing with regard to the research being reported. Two of the authors (AB, LuKr) are co-authors of the Measurements in the Addictions for Triage and Evaluation (MATE), which was used as an assessment tool in the current study. NS received honoraria for several activities (advisory boards, lectures, manuscripts) from the companies Abbvie, Medice, Reckitt-Benckiser/Indivior, and Sanofi-Aventis. During the last three years, he participated in clinical trials financed by the pharmaceutical industry. Otherwise, the authors declare that they have no competing interests.